Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Discovery To Creation: Highlights from the 2023 Single-Cell and AI in Medicine Symposium

    Aug 2, 2023, 01:00 AM by User Not Found
    Bio-IT World | The field of drug discovery is shifting its approach from viewing complex biology as something to be overcome using reductionist principles to something to embrace in a more holistic approach to cell biology.
    Full story
  • Not every protein-protein interaction impacts cancer drug design

    Aug 1, 2023, 09:12 AM by
    Researchers uncover a detailed action mechanism for protein MRG15, an important consideration for drugs targeting ASH1L which is overexpressed in many cancers. The findings from King Abdullah University of Science and Technology (KAUST), Saudi Arabia and the University of Michigan, U.S, could implicate the design of future cancer treatments.
    Full story
  • Platform Reduces Barriers Biologists Face In Accessing Machine Learning

    Aug 1, 2023, 01:00 AM by User Not Found
    Bio-IT World | A group of scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University and MIT are convinced that automated machine learning (autoML) is going to revolutionize biology by removing many of the technical barriers to using computational models to answer fundamental questions about sequences of nucleic acids, peptides, and glycans.
    Full story
  • African Pharmaceutical Market is expected to see a Double-Digit Growth by 2027 – Emerging Growth Opportunities in Africa

    Jul 28, 2023, 08:17 AM by
    Rapidly growing African population and urbanization, an increasing number of chronic diseases, and growing healthcare spending's are some of the primary factors driving the growth of the African pharmaceutical market.
    Full story
  • Revvity Signals Software and Scitara Expand Strategic Relationship to Accelerate Laboratory Digital Transformation

    Jul 28, 2023, 08:16 AM by
    Full story
  • Thermo Fisher Scientific Introduces New Liquid Chromatography Detector

    Jul 28, 2023, 08:16 AM by
    Full story
  • Huateng Pharma Announced To Attend CPhI Korea in August 2023

    Jul 27, 2023, 08:47 AM by
    Huateng Pharma is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on. We have a 34,000 square meter manufacturing site with advanced design concept of intelligent manufacturing, which can realize the integration of the production process and accomplish the complete transformation of lab scale - pilot plant - large-scale commercial production, with an annual capacity of more than 1 billion RMB. Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818
    Full story
  • Samsung Biologics Reports Second Quarter 2023 Financial Results

    Jul 27, 2023, 08:45 AM by
    Full story
  • Recent Cash Injection Boosts VectorBuilder to Unicorn Status

    Jul 27, 2023, 08:45 AM by
    VectorBuilder, a leading gene delivery technology company, announced with its latest cash injection that it reached a $1 billion valuation. VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside. It is also a full-service CRO and CDMO supporting customers in their entire drug discovery pipeline, with over 4000 institutional customers worldwide. Gene delivery technologies enable precise manipulation of genetic information in cells and organisms. Besides being the workhorse of life sciences research for many decades, gene delivery technologies can correct genetic disorders, develop personalized medicine, and even enhance crop yields. This has sparked tremendous interest among scientists, clinicians, and industry leaders, making it a sought-after area of innovation and investment.
    Full story
  • Illumina Announces New Genomics Alliance, Software for Analyzing Genomic Data, Understanding Disease Molecules, More

    Jul 27, 2023, 01:00 AM by User Not Found
    Bio-IT World | Illumina announces the five founding members of the Alliance of Genomic Discovery and launches the newest version of DRAGEN software, the Allen Institute for Immunology and Eli Lilly team up to better understand disease molecules, and crowd-sourced neuroscience. Plus, product updates, partnerships, and acquisitions from Sinequa, Lifebit, Arrayjet, BioIVT, and more.
    Full story
  • Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

    Jul 26, 2023, 07:57 AM by
    Biovian, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.
    Full story
  • Follow the Money: AI Platform for Acute Immune States, Acquisitions, Expanding Solutions Portfolio

    Jul 26, 2023, 01:00 AM by User Not Found
    Bio-IT World | AI platform used for acute immune states, acquisitions, solutions portfolio expansion, and more.
    Full story
  • Pharma CEOs pen open letter calling suppliers to commit to sustainability targets

    Jul 25, 2023, 09:23 AM by
    Signed by the CEOs of AstraZeneca, GSK, Merck, Novo Nordisk, Sanofi, Samsung Biologics, and the Chairman of Roche, the Health Systems Task Force is calling on suppliers to commit to joint, minimum climate and sustainability targets.
    Full story
  • TransCure bioServices expands reach into APAC with Preclina Inc partnership

    Jul 25, 2023, 09:23 AM by
    TransCure bioServices has expanded its reach in the APAC region by signing a strategic partnership with leading South Korean preclinical research company Preclina Inc.
    Full story
  • Jarrod Anderson and the Benefits of AI

    Jul 25, 2023, 01:00 AM by User Not Found
    Bio-IT World | As industries further explore AI, an abundance of new projects and ideas surface, and it can be difficult to decide where to focus.
    Full story
  • CD Genomics Launches Advanced Whole Exome Sequencing Service, Empowering Genetic Research

    Jul 24, 2023, 10:12 AM by
    Full story
  • CD Genomics Unveils Cutting-edge DAP-Seq Service Revealing the Hidden Secrets of DNA

    Jul 24, 2023, 10:12 AM by
    Full story
  • CD Genomics Redefines Genomic Research with Full-Length Transcripts Sequencing (Iso-Seq)

    Jul 24, 2023, 10:12 AM by
    Full story
  • BioIVT to Discuss its Pivotal Role in Liquid Biopsy Research at the AACC Annual Scientific Meeting and Clinical Lab Expo

    Jul 24, 2023, 09:26 AM by
    BioIVT’s standardized collection protocols and diverse donor base help facilitate molecular biomarker validation and ensure their clinical utility.
    Full story
  • Insilico Medicine Is Developing New Inhalable Formulation of First Generative AI Drug

    Jul 21, 2023, 12:16 PM by
    On the heels of the announcement of Phase II clinical trials for the first generative AI drug for the devastating lung disease idiopathic pulmonary fibrosis (IPF), clinical-stage drug discovery biotech Insilico Medicine has announced another breakthrough – an inhalation solution for its anti-fibrotic small molecule inhibitor designed to give patients in need another treatment option.
    Full story
  • «
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97 (current)
  • 98
  • 99
  • 100
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy